The preliminary results of our study, suggesting an increase in the number and functionality of cEPCs following treatment with an SGLT2 inhibitor, may have important future clinical implications in the treatment of cardiovascular diseases. This evidence concerns the gene SLC5A2 and cardiovascular disorder.